Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Voclosporin (Orelvo) vs placebo in active lupus nephritis
2016-004045-81Phase 3Completed
- Sponsor
- Aurinia Pharmaceuticals, Inc.
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in lupus nephritis (LN) comparing Voclosporin 23.7 mg BID with Placebo (2 arms). Primary endpoint: Renal response at Week 52. Started Mar 2017; status: completed.
02
Drugs
voclosporin
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on 2016-004045-81.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004045-81.